Compositions and methods for tumor-targeted delivery of effector molecules
View Patent ↗The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor cancer such as a carcinoma, melanoma, lymphoma, or sarcoma. The invention relates to the surprising discovery that effector molecules, which may be toxic when administered systemically to a host, can be delivered locally to tumors by attenuated tumor-targeted bacteria with reduced toxicity to the host. The application also discloses to the delivery of one or more optional effector molecule(s) (termed secondary effector molecules) which may be delivered by the attenuated tumor-targeted bacteria in conjunction with the primary effector molecule(s).
1. An attenuated tumor-targeted bacteria comprising a first nucleic acid molecule encoding a primary effector molecule operably linked to a eukaryotic promoter and a second nucleic acid molecule encoding a secondary effector molecule operably linked to a eukaryotic promoter, wherein said attenuated tumor-targeted bacteria is Salmonella , said primary effector molecule is endostatin, and said secondary effector molecules is bacteriocin release factor (BRP).
2. The attenuated tumor-targeted bacteria of claim 1 , wherein the BRP is obtained from the cloacin DF13 plasmid.
3. The attenuated tumor-targeted bacteria of claim 1 , wherein the Salmonella is an msbB Salmonella mutant.
4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an attenuated tumor-targeted bacteria comprising a first nucleic acid molecule encoding a primary effector molecule operably linked to a eukaryotic promoter and a second nucleic acid molecule encoding a secondary effector molecule operably linked to a eukaryotic promoter, wherein said attenuated tumor-targeted bacteria is Salmonella , said primary effector molecule is endostatin, and said secondary effector molecule is bacteriocin release factor (BRP).
5. The pharmaceutical composition of claim 4 , wherein the BRP is obtained from the cloacin DF13 plasmid.
6. The pharmaceutical composition of claim 4 wherein the Salmonella is an msbB Salmonella mutant.
7. A method for delivering a primary effector molecule to a subject to treat a solid tumor cancer, comprising administering to said subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an attenuated tumor-targeted bacteria comprising a first nucleic acid molecule encoding a primary effector molecule operably linked to a eukaryotic promoter and a second nucleic acid molecule encoding a secondary effector molecule operably linked to a eukaryotic promoter, wherein said attenuated tumor-targeted bacteria is Salmonella , said primary effector molecules is endostatin, and said secondary effector molecule is bacteriocin release factor (BRP).
8. The method of claim 7 , wherein the BRP is obtained from the cloacin DF13 plasmid.
9. The method of claim 7 , wherein the Salmonella is an msbB Salmonella mutant.